◀ Back to PRKAB1

PRKAB1 — RPS6KB1

Text-mined interactions from Literome

Tokunaga et al., Biochem Biophys Res Commun 2004 : Recent reports including our study have demonstrated the possible interplay between mTOR and AMPK signaling pathways, supporting a model in which mitochondrial dysfunction caused by the mitochondrial inhibitors or ATP depletion inhibits activation of p70 S6 kinase alpha (p70alpha) , a downstream effector of mTOR, by activating AMPK
Zito et al., J Biol Chem 2007 : Growth factor deprivation reduces cellular energy, and the energy sensing 5'-AMP activated protein kinase (AMPK) negatively regulates S6K1
Bae et al., Hepatology 2007 (Hypoglycemia...) : Moreover, oltipraz activated AMP activated protein kinase (AMPK), whose inhibition by a dominant negative mutant abolished S6K1 inhibition and protected insulin signaling, indicating that AMPK activation leads to S6K1 inhibition ... CONCLUSION : Our findings led to the identification of dithiolethione compounds that prevent insulin resistance through a mechanism involving AMPK mediated S6K1 inhibition and thereby sensitize hepatic insulin response
Hwahng et al., Hepatology 2009 (Fatty Liver) : Dithiolethiones, a novel class of adenosine monophosphate activated protein kinase ( AMPK ) activators, prevent insulin resistance through AMPK dependent p70 ribosomal S6 kinase-1 ( S6K1 ) inhibition
Hou et al., Endocrinology 2010 : In contrast, activation of AMPK inhibited LH-stimulated MTOR/S6K1 signaling and progesterone secretion
Liu et al., Biochim Biophys Acta 2012 (Insulin Resistance) : Consistent with this, inhibition of AMPK by compound C induced an enhanced phosphorylation of both S6K1 and Akt, and silencing of S6K1 with siRNA showed no effect on Akt phosphorylation in both the absence and presence of palmitate cultured myotubes